Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Lucy Gately(Walter and Eliza Hall Institute of Medical Research), Carmen Balañá(Institut Català d'Oncologia), Ross Jennens, Craig Underhill(AstraZeneca (United Kingdom)), Pedro Pérez‐Segura(Hospital Clínico San Carlos), Rosemary Harrup(University of Tasmania), Ian Collins(St. James's Hospital), Carlos Mesía(Institut Català d'Oncologia), Maria Martinez‐García(Hospital Del Mar), M. Alonso(Hospital Universitario Virgen del Rocío), Elizabeth Ahern(Monash Health), Anthony Dowling(Monash University), Sergio Peralta(Hospital Universitari Sant Joan de Reus), A. Long(Providence Portland Medical Center), Katharine Cuff(Eastern Health), Regina Gironés(Hospital Universitari i Politècnic La Fe), M Navarro(Instituto Ramón y Cajal de Investigación Sanitaria), M. Dumas(Walter and Eliza Hall Institute of Medical Research), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Robert M. Campbell(Children's Health Queensland Hospital and Health Service), Óscar Gallego(Hospital de Sant Pau), Stephen Brown(Ballarat Health Services), Ana Herrero(Hospital Universitario Miguel Servet), Matthew H. Wong(Westmead Hospital), Peter Gibbs(Memorial Sloan Kettering Cancer Center), J. Fuster(Hospital Universitario Son Espases), M. Rosenthal(Peter MacCallum Cancer Centre), Javier Torres(Goulburn Valley Health), Zarnie Lwin(The University of Queensland), M. Covela(Hospital Universitario Lucus Augusti), Adam Cooper(Liverpool Hospital), Estela Pineda(Hospital Clínic de Barcelona), Sudeep S. Gill(Providence Health Care)
Cited by 3
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Histone Modifications and Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.1k
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Federated learning enables big data for rare cancer boundary detection
|Nature Communications|2022|364